Immune to Cancer: The CRI Blog
-
Our Supporters #WearWhite for a Future Immune to Cancer
On June 15, hundreds of scientists, patients, advocates, and healthcare professionals donned white apparel for our sixth…
-
30 Days of CRI Impact: Understanding Immune Checkpoints and Pathways
This week’s CRI breakthroughs deal with the development of checkpoint immunotherapy and other advances that have helped…
-
First Checkpoint Immunotherapy Approved for Advanced Cervical Cancer
Pembrolizumab, a PD-1-targeting immunotherapy, was approved for recurrent advanced cervical cancer that expresses PD-L1.
-
30 Days of CRI Impact: Laying the Foundation for Cancer Immunotherapy
The first nine days in June 2018 highlight early discoveries that helped establish cancer immunotherapy's foundations.
-
ASCO18 Recap: How Immunotherapy is Revolutionizing Cancer Treatment
Our recap of the immunotherapy highlights from the world’s largest clinical cancer conference in 2018
-
What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2018
Drs. Charles G. Drake, Catherine Diefenbach, and Jeffrey S. Weber discuss the latest cancer immunotherapy advances out of the 2018 ASCO annual meeting.
-
ASCO18 Update: Using Biomarkers to Improve Immunotherapy
The final day of ASCO18 focused on biomarkers’ potential to improve immunotherapy as well as the next-generation…
-
ASCO18 Update: Much Ado About Melanoma (and Lung Cancer, Too)
Day 4 of ASCO18 focused on the past, present, and future of melanoma treatment, and also revealed…
-
ASCO18 Update: Immunotherapy Progress in Lung Cancer, New Promise in Ovarian Cancer
Day 3 of ASCO18 revealed more of immunotherapy’s benefits in lung cancer, especially as a first-line option,…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.